Following the success of the first xenotransplantation of a pig kidney into a human patient in August 2023, significant advances have been made thanks to the molecular analyses conducted by the teams at the Paris Institute for Transplantation and Organ Regeneration (PITOR) of Université Paris Cité, led by Professor Alexandre Loupy. PITOR, a European leader in organ transplantation and regeneration, has been selected to host the BANFF 2024 international conference, co-organized by Professors Carmen Lefaucheur and Alexandre Loupy. This conference will mark the establishment of the first BANFF classification for xenograft rejection.
Xénotransplantation
© Alexandre Loupy
The conference will open on September 16, 2024, at the National Academy of Medicine and will continue from September 17 to 20 at the Université Paris Cité headquarters.The inclusion of xenografts in the international BANFF classification is a world first. This classification of graft rejection, based on internationally developed and validated criteria, is a crucial step towards the standardization and advancement of xenotransplantation, a revolutionary practice in medicine.
The PITOR Institute at Université Paris Cité, recognized as a European leader in organ transplantation and regeneration, has been chosen to host this international conference. This event provides a unique opportunity to showcase the excellence of French research and medical innovation.
Global experts in organ transplantation, along with the editors-in-chief of the six leading international scientific journals-The Lancet, The New England Journal of Medicine (NEJM), Journal of the American Society of Nephrology (JASN), Kidney International, American Journal of Transplantation (AJT), and Transplant
International—will be present in Paris from September 16 to 20, 2024. The prestigious venues of the National Academy of Medicine and the headquarters of Université Paris Cité in the heart of Paris will serve as the setting for this major global event.
PITOR – The 29 research units and teams, along with the clinical services gathered within the PITOR Institute (Paris Institute for Transplantation and Organ Regeneration), conduct their research based on four major areas: understanding and treating organ rejection (kidney, heart, lung, liver, pancreas, and composite tissues) by addressing pathophysiological mechanisms to optimize therapeutic management of patients; diagnosis and monitoring by developing innovative tools to transform the care pathway for transplant patients. The institute also focuses on optimizing, allocating, and preserving organs by developing innovative approaches based on artificial intelligence. Finally, part of their work involves regenerative medicine, through the creation of organs, organoids, and organs-on-chips, in order to provide new tools and products to create, refurbish, or replace organ tissues. https://paristransplantgroup.com/
Read more
Highly Cited Researchers 2024: 26 citations for Université Paris Cité
Clarivate has released the list of 126 scientists whose first affiliation is with a research institution based in France and who are featured in the 2024 ranking of the 6,886 most highly cited researchers. With 26 first-affiliation mentions, Université Paris Cité has...
read moreLooking back at The Guild conference: Artificial Intelligence in Higher Education and Research
On November 6th 2024, Université Paris Cité and Université PSL brought together the communities of The Guild of European Research-Intensive Universities for an event about artificial intelligence and its impact on universities, at the PariSanté Campus. Stéphanie...
read more[International Partnership] Major Women’s Health Conference in Singapore
From October 24 to 26, a delegation of fourteen professors, lecturers and researchers from the Faculty of Health, led by Dean Matthieu Resche-Rigon and the co-director of the Institute of Women’s Health, Vassilis Tsatsaris, visited Singapore for the Women’s Health Conference 2024.
read moreInternational Study Characterises for the First Time a New Type of Kidney Transplant Rejection
In cases of kidney failure, transplantation is the treatment of choice. However, the risk of rejection remains high. A better understanding of the immune response to kidney transplant rejection - and in particular the phenomenon of microvascular inflammation - could...
read more